Global Gene Editing Therapy Market Growth (Status and Outlook) 2024-2030
The global Gene Editing Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Gene Editing Therapy Industry Forecast” looks at past sales and reviews total world Gene Editing Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Editing Therapy sales for 2023 through 2029. With Gene Editing Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Editing Therapy industry.
This Insight Report provides a comprehensive analysis of the global Gene Editing Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gene Editing Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Editing Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Editing Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Editing Therapy.
United States market for Gene Editing Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Gene Editing Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Gene Editing Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Gene Editing Therapy players cover CRISPR Therapeutics, Beam Therapeutics, Editas Medicine, Verve Therapeutics, Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Editing Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
In Vivo Gene Editing
In Vitro Gene Editing
Segmentation by Application:
Thalassemia
Cancer
Cystic Fibrosis
Muscular Dystrophy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
In Vivo Gene Editing
In Vitro Gene Editing
Segmentation by Application:
Thalassemia
Cancer
Cystic Fibrosis
Muscular Dystrophy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CRISPR Therapeutics
Beam Therapeutics
Editas Medicine
Verve Therapeutics
Bluebird Bio
Intellia Therapeutics
Vertex Pharmaceuticals
Caribou Biosciences
Please note: The report will take approximately 2 business days to prepare and deliver.